CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference

CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026.

Rhea-AI Summary

CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026. Management plans to discuss recent progress in the neflamapimod clinical development program. The fireside chat is scheduled from 11:30–11:55 AM ET and will be available via webcast, including through the Investor section of the CervoMed website.

Argus Aug 5 session 6 alerts

+0.36% close to close 1.2x rel. volume Open Argus

Details

News Market Reaction – CRVO

+11.3% Peak Tracked

-2.4% Trough Tracked

$27.31M Market Cap

In the Aug 5 session, CRVO gained 0.36%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.3% during that session. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Net Buying totaled 2,866,242 shares with zero reported sales in the recent insider record. That cont...

Analysis

Net Buying totaled 2,866,242 shares with zero reported sales in the recent insider record. That context supports monitoring the conference update alongside the effective S-3 resale registration and its resale structure.

Key Figures

Conference edition: 46th annual conference Conference date: August 11, 2026 Fireside chat time: 11:30–11:55 AM ET

Conference edition

46th annual conference

Canaccord Genuity Growth Conference

Conference date

August 11, 2026

Fireside chat and investor meetings

Fireside chat time

11:30–11:55 AM ET

August 11, 2026

Previous Clinical trial Reports

5 past events · Latest: Jul 09

Same Type 5 events

1. Jul 09

   Phase 2 enrollment

   24h Move

   +9.7%

   Completed enrollment in a 25-patient Phase 2a nfvPPA study.

2. Mar 04

   Phase 3 dosing selection

   24h Move

   +0.3%

   Selected 50 mg three-times-daily dosing for the planned DLB Phase 3 trial.

3. Mar 10

   Phase 2b extension results

   24h Move

   +6.3%

   Reported positive extension results with improvements versus prior capsules and placebo.

4. Dec 10

   Phase 2b topline data

   24h Move

   -78.9%

   Reported failure to achieve statistical significance on primary and key secondary endpoints.

5. Nov 27

   Orphan drug designation

   24h Move

   +14.7%

   Received FDA Orphan Drug Designation for neflamapimod in frontotemporal dementia.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the Canaccord Genuity 46th Annual Growth Conference, being held in Boston, MA, on Tuesday, August 11, 2026.

During the fireside chat, management will share recent progress in neflamapimod's clinical development program.

Presentation Details
Format: Fireside Chat
Date: Tuesday, August 11, 2026
Time: 11:30 – 11:55 AM ET
Webcast Link: https://event.summitcast.com/view/WuFmFdTcA9mVsUGHZJFU62/guest_book?session_id=CbcwtmiHhUmzr5EAgGgHjJ

The webcast of the fireside chat will be accessible in the Investor section of the CervoMed website https://www.cervomed.com/.

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is CervoMed (NASDAQ: CRVO) presenting at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026?

CervoMed will host a fireside chat highlighting recent progress in its neflamapimod clinical development program. According to CervoMed, management will also participate in one-on-one investor meetings during the conference in Boston, providing updates on its work in age-related brain disorders.

When is CervoMed’s neflamapimod fireside chat scheduled at the Canaccord Genuity conference in 2026?

CervoMed’s fireside chat is scheduled for August 11, 2026, from 11:30 to 11:55 AM ET. According to CervoMed, this session will focus on recent progress in the neflamapimod clinical development program and will be accessible via a live webcast.

How can investors access the CervoMed (CRVO) webcast from the Canaccord Genuity 46th Annual Growth Conference?

Investors can access the CervoMed webcast through a dedicated webcast link and the Investor section of the CervoMed website. According to CervoMed, the fireside chat on August 11, 2026, will be streamed online for remote participants and shareholders.

What is neflamapimod and why is it important to CervoMed’s August 2026 presentation?

Neflamapimod is CervoMed’s clinical-stage drug candidate targeting age-related brain disorders. According to CervoMed, the August 11, 2026 fireside chat at the Canaccord Genuity conference will highlight recent progress in neflamapimod’s clinical development program for interested investors and stakeholders.

Where is the Canaccord Genuity 46th Annual Growth Conference featuring CervoMed (CRVO) being held?

The Canaccord Genuity 46th Annual Growth Conference featuring CervoMed is being held in Boston, Massachusetts. According to CervoMed, company management will join a fireside chat and investor meetings there on Tuesday, August 11, 2026, to discuss its neflamapimod program.

Will CervoMed hold one-on-one investor meetings during the Canaccord Genuity 2026 conference?

Yes, CervoMed plans to hold one-on-one investor meetings alongside its fireside chat at the conference. According to CervoMed, these meetings at the Canaccord Genuity 46th Annual Growth Conference will provide additional interaction with investors beyond the scheduled webcast session.